Germany suspends 80 products linked to Indian CRO problems
This article was originally published in Scrip
The German regulatory agency BfARM has suspended 80 generic products whose marketing authorizations relied on bioequivalence tests conducted by the Indian CRO GVK Biosciences. The company's procedures have been called into doubt following a GCP inspection earlier this year which suggested shortcuts had been taken with BE studies.
You may also be interested in...
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
The EU’s massive economic stimulus package, Next Generation EU, includes a wide-ranging health program that aims to make health systems more resilient to future threats by supporting the development and manufacture of affordable new medicines and vaccines as well as measures to prevent drug shortages.